The FDA clearance is a transformative catalyst for a $21M market-cap biotech. Monitor for Phase 2 trial initiation details and enrollment timelines. The extended cash runway through October 2027 reduces near-term dilution risk, making the stock more attractive for event-driven positions ahead of data readouts.
Price Chart
Executive Summary
Quantum BioPharma reported Q2 2026 results showing improved liquidity (cash + digital assets of ~$9.5M, up from $4.1M) and a 53% reduction in operating expenses. The key catalyst is the subsequent FDA approval of an IND for Lucid-MS Phase 2 trial in progressive multiple sclerosis, a pivotal milestone for the company's lead asset. The combined financial discipline and regulatory clearance significantly reduce near-term risk and open a path to value inflection.
Key Facts
- FDA approved IND for Lucid-MS Phase 2 trial in progressive MS on August 10, 2026
- Combined cash, cash equivalents, and digital assets ~$9.5M at June 30, 2026, up from $4.1M at Dec 31, 2025
- Total operating expenses decreased 53% YoY to $2.29M in Q2 2026
- Cash used in operating activities fell 44% to $3.46M for H1 2026
- Management confirms liquidity sufficient to fund operations to at least October 2027
- Total shareholders' equity increased 19% to $6.09M
- Working capital improved to $1.66M from $0.42M at year-end 2025
Financial Impact
FDA IND approval for Lucid-MS Phase 2 trial in progressive MS (global market expected ~$38.62B by 2030 per Grand View Research); cash position strengthened to ~$9.5M with extended runway to October 2027
Risk Factors
- Clinical trial failure or delays in Lucid-MS Phase 2
- Potential need for additional financing if burn rate increases or digital asset values decline
- Low liquidity and high volatility typical of micro-cap biotech stocks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005524 |
| Document: f6k_081426.htm | 0001171843-26-005524 |
| Document: 0001171843-26-005524-index-headers.html | 0001171843-26-005524 |
| Document: 0001171843-26-005524-index.html | 0001171843-26-005524 |
| Document: 0001171843-26-005524.txt | 0001171843-26-005524 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 6-K | $3.11 | awaiting T+20 | — | $2.33 (−25.08%) |
Oct 6, 2026 21d ago | 6-K | $3.09 | awaiting T+20 | — | $2.33 (−24.60%) |
Oct 6, 2026 21d ago | Press Release | $3.09 | awaiting T+20 | — | $2.33 (−24.60%) |
Oct 5, 2026 22d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.33 (−28.75%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.33 (−41.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.33 (−37.37%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.33 (−37.37%) |
Sep 15, 2026 6w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.33 (−32.66%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.33 (−24.35%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.33 (−24.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers